EMBC · XBRL financial data

Embecta financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (EMBC's year ends in late September)

In millions of dollars	Q4 FY23Sep 30, 2023	Q1 FY24Dec 31, 2023	Q2 FY24Mar 31, 2024	Q3 FY24Jun 30, 2024	Q4 FY24Sep 30, 2024	Q1 FY25Dec 31, 2024	Q2 FY25Mar 31, 2025	Q3 FY25Jun 30, 2025	Q4 FY25Sep 30, 2025	Q1 FY26Dec 31, 2025	Q2 FY26Mar 31, 2026	Q3 FY26Jun 30, 2026
Revenue from contracts with customers	282*	277	287	273	286*	262	259	296	264*	261	222	272
Cost of goods and services sold	100*	91	102	82	112*	105	95	98	106*	100	94	118
Gross profit	182*	186	185	190	174*	157	164	197	159*	162	128	153
Research and development	24*	20	18	20	20*	20	8	4	5*	5	5	6
Selling, general and administrative	96*	90	92	86	97*	81	80	84	87*	78	76	79
Total operating expenses	156*	140	146	134	148*	128	101	103	102*	78	93	105
Other operating income (expense)	year only	(1)	(1)	(0)	0*	0	(0)	(1)	(0)*	4	(11)	(20)
Operating income (loss)	26*	46	39	56	26*	29	63	94	57*	83	35	49
Income tax expense (benefit)	(1)*	(6)	(19)	12	(22)*	(1)	12	27	3*	15	14	7
Net income (loss)	6*	20	29	15	15*	0	24	46	26*	44	(4)	21
Earnings per share, basic USD per share	0.10*	0.35	0.50	0.25	0.25*	0.00	0.40	0.78	0.45*	0.75	(0.07)	0.36
Earnings per share, diluted USD per share	0.10*	0.35	0.50	0.25	0.24*	0.00	0.40	0.78	0.44*	0.74	(0.07)	0.36
Weighted average shares, basic millions of shares	57*	57	58	58	58*	58	58	58	59*	59	59	58
Weighted average shares, diluted millions of shares	58*	58	58	58	60*	59	59	58	60*	59	59	59

Fiscal quarters (EMBC's year ends in late September)

In millions of dollars	Q4 FY23Sep 30, 2023	Q1 FY24Dec 31, 2023	Q2 FY24Mar 31, 2024	Q3 FY24Jun 30, 2024	Q4 FY24Sep 30, 2024	Q1 FY25Dec 31, 2024	Q2 FY25Mar 31, 2025	Q3 FY25Jun 30, 2025	Q4 FY25Sep 30, 2025	Q1 FY26Dec 31, 2025	Q2 FY26Mar 31, 2026	Q3 FY26Jun 30, 2026
Cash and cash equivalents	327	299	300	275	268	210	209	231	226	201	185	215
Accounts receivable	17	96	124	172	193	181	186	183	146	159	147	182
Inventory	152	149	153	186	172	169	169	190	179	182	193	214
Total current assets	749	720	710	781	761	667	643	682	631	620	608	705
Right-of-use asset	23	22	22	20	23	19	21	20	20	19	18	18
Goodwill	16	16	16	16	16	16	16	15	15	15	15	40
Total assets	1,214	1,218	1,200	1,268	1,285	1,150	1,120	1,157	1,091	1,064	1,029	1,265
Accrued liabilities	118	122	120	142	134	127	123	129	99	112	114	139
Current portion of long-term debt	10	10	10	10	10	10	10	10	10	10	10	139
Total current liabilities	354	327	310	371	374	298	259	276	262	235	247	420
Long-term debt	1,594	1,593	1,592	1,591	1,565	1,535	1,509	1,459	1,389	1,353	1,317	1,316
Lease liability, non-current	15	15	14	14	12	11	11	11	10	10	9	9
Accumulated deficit	(541)	(530)	(510)	(504)	(499)	(508)	(494)	(457)	(446)	(411)	(425)	(404)
Total stockholders' equity	(822)	(794)	(770)	(764)	(738)	(769)	(736)	(670)	(651)	(613)	(626)	(613)
Total liabilities and equity	1,214	1,218	1,200	1,268	1,285	1,150	1,120	1,157	1,091	1,064	1,029	1,265
Common shares outstanding (cover page) millions of shares	57	58	58	58	58	58	58	58	59	59	59	57

Fiscal quarters (EMBC's year ends in late September)

In millions of dollars	Q4 FY23Sep 30, 2023	Q1 FY24Dec 31, 2023	Q2 FY24Mar 31, 2024	Q3 FY24Jun 30, 2024	Q4 FY24Sep 30, 2024	Q1 FY25Dec 31, 2024	Q2 FY25Mar 31, 2025	Q3 FY25Jun 30, 2025	Q4 FY25Sep 30, 2025	Q1 FY26Dec 31, 2025	Q2 FY26Mar 31, 2026	Q3 FY26Jun 30, 2026
Net income (loss)	6*	20	29	15	15*	0	24	46	26*	44	(4)	21
Stock-based compensation	5*	7	7*	6*	6*	9	7*	6*	10*	6	6*	4*
Depreciation and amortization	9*	9	9*	9*	10*	9	9*	9*	13*	10	10*	11*
Net cash from operating activities	30*	(13)	24*	(2)*	27*	(5)	32*	81*	84*	17	31*	42*
Purchases of property and equipment	9*	3	3*	10*	0*	2	0*	0*	7*	1	1*	1*
Net cash from investing activities	(9)*	(3)	(3)*	(10)*	0*	(2)	(0)*	(0)*	(7)*	10	(1)*	(130)*
Dividends paid	9*	9	9*	9*	9*	9	9*	9*	9*	9	9*	1*
Proceeds from long-term debt	0*	—	—	—	year only	—	—	—	—	—	—	—
Repayments of long-term debt	2*	2	2*	2*	27*	32	27*	52*	72*	38	38*	2*
Net cash from financing activities	(10)*	(14)	(12)*	(12)*	(37)*	(45)	(37)*	(63)*	(82)*	(52)	(42)*	112*
Net change in cash	9*	(28)	8*	(25)*	(8)*	(58)	(4)*	21*	(5)*	(24)	(11)*	25*

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Embecta	215	272	42*	56.7M	—	Q3 FY26 10-QJun 30, 2026
Mimedx Group	121	62	3.9*	145.9M	—	Q3 FY26 10-QSep 30, 2026
SI-BONE	35	56	5.9*	45.1M	—	Q3 FY26 10-QSep 30, 2026
Biolife Solutions	24	not reported	6.3*	48.9M	—	Q2 FY26 10-QJun 30, 2026
Beta Bionics	82	36	(12)*	54.4M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
Kestra Medical Technologies	69	31	(32)	59.6M	4.9 quarters	Q1 FY26 10-QJul 31, 2026
Integra Lifesciences Holdings	252	411	96*	77.8M	—	Q3 FY26 10-QSep 30, 2026
Cadre Holdings	54	207	22*	42.8M	—	Q2 FY26 10-QJun 30, 2026
Avanos Medical	66	182	(12)	46.8M	5.3 quarters	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.